TissueGen, Inc. Appoints Keith Brown as President and CEO

TissueGen, Inc. announced the appointment of Keith W. Brown as President and Chief Executive Officer. Dr. Kevin Nelson, formerly President and Chief Science Officer, will focus his efforts as Chief Science Officer. Dr. James Dukowitz, formerly Chairman and CEO, will continue to serve as Chairman of the Board. Mr. Brown will also serve on the TissueGen Board of Directors.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, TX (PRWEB) January 14, 2005

Mr. Brown has 15 years experience with venture-backed biotechnology companies following 10 years in the medical diagnostics industry. He was the founding President/CEO of GeneScreen, building it into a $15 million, multi-location laboratory testing company in the field of DNA analysis. GeneScreen was sold to Orchid BioSciences in 2000 where Mr. Brown managed their Identity Genomics business to over $30 million. Mr. Brown’s experience includes leading five rounds of venture financing with GeneScreen and assisting in Orchid’s IPO, four acquisitions, two divestitures, and all aspects of budgeting, financing, marketing, sales, operations and strategic business planning.

According to Dr. Dukowitz, "The Board of Directors of TissueGen is very pleased to have Keith Brown serve as President, Chief Executive Officer and board member. He brings a wealth of industry and management experience to the position, and will be essential to continuing the strong momentum and maturation of the company at a critical point in its development.”

“I am delighted to have Keith join TissueGen and lead its management team,” said Kevin Nelson, Ph.D., CSO and former President of TissueGen. “He brings a valuable combination of entrepreneurial experience and seasoned management leadership to the company and I believe his addition will help us continue and accelerate our transition to a commercial enterprise.”

TissueGen has received corporate management and advisory services under a contract with Technology Innovation Group (http://www.innovationmatters.com) from March 2003 until December 2004. TissueGen has recently undertaken with partners new research projects using its proprietary technology for implantable stent applications. The company also completed a sponsored research project using its platform drug delivery format to validate a novel drug application. It has successfully begun its first fund-raising, which it anticipates completing in early 2005.

About TissueGen

TissueGen, Inc., a Delaware corporation based in Dallas, Texas, was founded in 2000 to commercialize drug-releasing bioresorbable polymer fiber scaffolds developed by Dr. Kevin Nelson at The University of Texas at Arlington. TissueGen is a corporate graduate of the business incubator located at UT Arlington. TissueGen’s proprietary technology combines drug delivery with tissue engineering to control the timing and location of tissue growth. These fibers are uniquely designed to meet the current challenges of tissue engineering and drug delivery in some of the fastest growing markets, including cardiovascular stents, advanced wound care and nerve regeneration.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information contact Keith Brown at (214) 351-1922.

###


Contact